Literature DB >> 23625297

Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide.

Hiroki Kato1, Yasushi Onishi, Yoko Okitsu, Yuna Katsuoka, Tohru Fujiwara, Noriko Fukuhara, Kenichi Ishizawa, Masanori Takagawa, Hideo Harigae.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23625297     DOI： 10.1007/s00277-013-1761-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  3 in total

1.  Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma.

Authors:  Nilanjan Ghosh; Noah Tucker; Marianna Zahurak; Jocelyn Wozney; Ivan Borrello; Carol Ann Huff
Journal:  Am J Hematol       Date:  2014-04-26       Impact factor: 10.047

2.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

3.  Roxithromycin monotherapy inducing a partial response in a patient with myeloma: a case report.

Authors:  Kern Y Chai; Anna L Byrne; Ian M Morison
Journal:  J Med Case Rep       Date:  2018-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.